The State Board of Health (Board) is temporarily pausing certain newborn screening (NBS) policy activities due to current budget constraints at the Department of Health (Department). The Department requested the Board pause these activities at its April 8, 2026, meeting during updates from Department leadership and NBS program staff on the state’s fiscal outlook and current operational capacity.
Effective July 1, 2026, the Board will implement a 12-month pause on specific NBS policy actions, including advancing rulemaking petitions and filing new rulemaking notices. Additionally, the Board will implement an immediate pause on convening NBS Technical Advisory Committees (TACs). This includes postponing the TAC meeting previously scheduled for April 29, 2026, to review Infantile Krabbe Disease. The pause may be extended if necessary.
The Board has directed Board staff to work closely with the Department and provide an update, along with a proposed path forward. The Board is committed to newborn screening in Washington state and will provide updates and information on this webpage as it becomes available.
Summary
What is Newborn Screening (NBS)?
All babies born in Washington State are screened shortly after birth. The Washington State Department of Health (Department) conducts this NBS testing using a small blood spot sample collected from a baby’s heel.
NBS checks for certain rare, serious, and treatable health conditions. Without early detection and treatment, these conditions can cause serious illness, lifelong disability, or death. Screening helps ensure babies get the care they need as early as possible.
For More Information
Statutory Authority: RCW 70.83.050
Board Contact: Molly Dinardo, molly.dinardo@sboh.wa.gov
Department of Health Contact: Megan McCrillis, megan.mccrillis@doh.wa.gov
To receive future updates on newborn screening please complete the NBS interest form online.
Additional Background
The Role of the Washington State Board of Health
Washington law (RCW 70.83.050) directs the Washington State Board of Health (Board) to set the rules for the Department’s NBS Program. One of the Board’s primary responsibilities is deciding which health conditions all babies born in Washington must be screened for. This list, known as the mandatory NBS panel, is defined in WAC 246-650-020.
The Board also:
- Reviews requests to consider new conditions for NBS.
- Convenes expert Technical Advisory Committees (TACs) to evaluate potential conditions and determine whether they meet the Board’s screening criteria.
- Reviews TAC recommendations and makes final decisions about adding new conditions to the NBS panel.
- Ensures decisions are based on scientific evidence, that babies who screen positive can reasonably access diagnosis and treatment, and that the benefits of screening outweigh potential harms.
- Monitors federal recommendations, such as the Health Resources and Services Administration’s Recommended Uniform Screening Panel (RUSP), while maintaining state-level decision-making authority.
- Conducts rulemaking to formally add new conditions to the mandatory screening panel once the Department and Washington State Health Care Authority receive legislative approval to increase the newborn screening fee.
Reviewing New Conditions
The Board and Department use a well-established process to review health conditions for possible addition to the state mandatory NBS panel. This process is designed to be fair, transparent, and based on the best available evidence. It prioritizes scientific evidence, ethics, equity, cost-effectiveness, and the benefits and harms of universal screening in Washington State.
Requests to review a condition may come from the public (by submitting a petition for rulemaking), the Legislature, Department of Health staff, or State Board of Health Members.
When a condition is ready for review, the Board convenes a multidisciplinary Technical Advisory Committee (TAC). TAC members include experts across the NBS system of care. The TAC evaluates the condition using the Board’s Newborn Screening Process and Criteria (last updated August 20, 2025) and provides recommendations to help the Board make an informed decision.
Conditions Recently Reviewed, Approved, and Pending Legislative Action
After the Board approves a new condition, screening cannot begin until additional steps are completed. The Department must receive legislative approval to increase the NBS fee, which pays for new tests, follow-up services, and administrative costs. The Washington State Health Care Authority (HCA), which covers more than 40% of births in the state, must also update Medicaid managed care rates to reflect the increased fee.
The following conditions have been approved by the Board and are awaiting legislative action:
- Wilson Disease
- Reviewed by the TAC: June 17, 2025
- Wilson Disease TAC Meeting Materials
- Approved by the Board: August 20, 2025
Delayed Condition Reviews
On April 8, 2026, the Board implemented an immediate pause on convening NBS TACs for a 12-month period with a possibility of an extension. This includes postponing the TAC meeting previously scheduled for April 29, 2026, to review Infantile Krabbe Disease.
- Infantile Krabbe Disease
- April 8, 2026, Meeting Minutes - Available June 4, 2026
- Metachromatic Leukodystrophy (MLD)
- Petition for rulemaking reviewed and denied: March 2026.
- Response letter to the petitioner
Conditions Recently Reviewed and Not Approved
- Mucopolysaccharidosis Type II (MPS II/Hunter Syndrome)
- Reviewed March 17, 2026
- MPS II TAC Meeting Materials
- Reviewed and denied by the Board: April 8, 2026
- April 8, 2026, MPS II Presentation
- April 8, 2026, Meeting Minutes - Available by June 4, 2026
- 3-methylcrotonyl-CoA carboxylase (3MCC) deficiency
- Reviewed December 9, 2025
- 3MCC TAC Meeting Materials
- Reviewed and denied by the Board: January 14, 2026
- January 14, 2026, 3MCC Presentation
- January 14, 2026, Meeting Minutes
- Congenital cytomegalovirus (cCMV) - required by SB 5829
- Reviewed February and March 2025
- cCMV TAC Meeting Materials (February) (March)
- Reviewed and denied by the Board: April 9, 2025
- Legislative report: cCMV legislative report (December 2025)
- Branched chain ketoacid dehydrogenase kinase (BCKDK) deficiency – required by SB 6234
- Reviewed January 2025
- BCKDK deficiency meeting materials
- Reviewed and denied by the Board: March 12, 2025
- Legislative report: BCKDK deficiency legislative report (June 2025)
Past Work
This section includes conditions reviewed or considered within the past two years that are no longer under active review. Older materials are removed unless there is a specific need to retain them.
- Adding Ornithine Transcarbamylase Deficiency (OTCD), Guanidinoacetate methyltransferase (GAMT) Deficiency, and Arginase 1 Deficiency (ARG1-D) - Newborn Screening - Adding OTC Deficiency, GAMT Deficiency, and ARG1-D | SBOH
- 2024 Newborn Screening Criteria Review Project
Related Links
- Department of Health Request to Temporarily Halt Certain Newborn Screening Activities Due to Budget Constraints
- Newborn Screening 2024 Criteria Review
- Federal Recommended Uniform Screening Panel (RUSP)
Submit a Condition for Review